Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.

Georgie WestonCaroline DombrowskiMichael J HarveyThomas IftnerMaria KyrgiouChristina FountaElisabeth J Adams

Published in: BMJ open (2020)

Using the Aptima mRNA assay versus a DNA assay would almost certainly yield cost savings and reduce unnecessary testing and procedures, benefiting the NHS and women in the CSP.

Keyphrases

high throughput
high grade
cervical cancer screening
patient safety
randomized controlled trial
binding protein
metabolic syndrome
pregnancy outcomes
quality improvement